P2RX7 and major depressive disorder: This was the first study to investigate the safety and pharmacokinetics of the CNS penetrant and selective P2X7 receptor antagonist JNJ-54175446 in MDD, and to explore its potential effects on mood-related phenomena such as reward propensity and changes in peripheral cytokine production following TSD.